Valuation : Genmab A/S

Market Cap 127B 19.81B 17.05B 16.05B 14.63B 27.37B 1,885B 27.48B 190B 73.54B 961B 74.4B 72.79B 3,043B P/E 2026 *
27x
P/E 2027 * 19x
Enterprise Value 147B 22.8B 19.62B 18.47B 16.83B 31.49B 2,169B 31.61B 219B 84.61B 1,105B 85.6B 83.74B 3,501B EV / Sales 2026 *
5.06x
EV / Sales 2027 * 4.11x
Free-Float
94.3%
Yield 2026 *
-
Yield 2027 * -
1 day-1.43%
1 week-1.89%
Current month+0.57%
1 month+6.75%
3 months+32.51%
6 months+23.71%
Current year+5.28%
1 week 2,130
Extreme 2130
2,209
1 month 1,973.5
Extreme 1973.5
2,232
Current year 1,512
Extreme 1512
2,257
1 year 1,512
Extreme 1512
2,257
3 years 1,157
Extreme 1157
2,710
5 years 1,157
Extreme 1157
3,327
10 years 786.2
Extreme 786.2
3,327
Manager TitleAgeSince
Chief Executive Officer 65 2010-05-31
Director of Finance/CFO 48 2020-02-29
Chief Tech/Sci/R&D Officer - 2024-08-15
Director TitleAgeSince
Director/Board Member 75 2003-10-31
Director/Board Member 58 2014-12-31
Director/Board Member 75 2014-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
12/1/25 Exercice

Director

189 0.0003%
12/1/25 Exercice

Director

189 0.0003%
12/1/25 Exercice

Director

283 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
-1.43%-1.89%+21.32%-19.01% 20.11B
-0.94%-0.71%+45.60%+103.25% 69.19B
-0.07%-3.93%+32.54%+78.50% 62.97B
+3.13%+1.71%-12.50%+390.48% 27.27B
-2.95%-6.59%+25.96%+10.91% 25.8B
-0.54%-5.47%-3.88%-18.31% 24.78B
-4.27%+3.07%+211.22%+362.48% 18.47B
-1.04%-4.43%-5.13%+507.94% 14.88B
+1.14%-0.34%+52.38%+163.82% 14.29B
+1.50%+20.14%-6.83%+1,038.96% 13.79B
Average -0.58%+1.49%+36.07%+261.90% 29.15B
Weighted average by Cap. -0.57%-0.22%+35.48%+182.12%

Financials

2026 *2027 *
Net sales 28.95B 4.5B 3.87B 3.65B 3.32B 6.22B 428B 6.24B 43.24B 16.71B 218B 16.91B 16.54B 691B 33.72B 5.24B 4.51B 4.25B 3.87B 7.24B 499B 7.27B 50.35B 19.46B 254B 19.69B 19.26B 805B
Net income 4.93B 767M 660M 621M 566M 1.06B 72.95B 1.06B 7.36B 2.85B 37.16B 2.88B 2.82B 118B 7.16B 1.11B 959M 903M 822M 1.54B 106B 1.55B 10.7B 4.13B 54.01B 4.18B 4.09B 171B
Net Debt 19.17B 2.98B 2.57B 2.42B 2.2B 4.12B 284B 4.14B 28.63B 11.07B 145B 11.2B 10.95B 458B 11.01B 1.71B 1.47B 1.39B 1.26B 2.37B 163B 2.37B 16.44B 6.35B 83B 6.43B 6.29B 263B
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,119
Date Price Change Volume
26-09-09 DKK 2,134.00 -1.43% 97,088
26-09-08 DKK 2,165.00 +1.12% 61,723
26-09-07 DKK 2,141.00 -1.11% 38,161
26-09-04 DKK 2,165.00 -1.46% 85,258
26-09-03 DKK 2,197.00 +1.01% 95,427
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
2,134.00DKK
Average target price
2,453.79DKK
Spread / Average Target
+14.99%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GMAB Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!